SGMT: Denifanstat's phase III acne trial launches soon, aiming for rapid market entry and long exclusivity
Denifanstat, a novel oral FASN inhibitor, is advancing to a US phase III acne trial with strong efficacy and safety data, targeting a large unmet need. Premium pricing and broad payer support are anticipated, with patent protection extending to 2037 and a second-generation molecule in development.B…